Desiree Cox, MBBS, PhD

A large multinational observational study of patients with hepatitis C reveals etiology does not play a major role in HCV survival rates and that early detection and access to treatment have a greater impact.

Preliminary results from the M12-999 study show that treatment with ABT-450/ritonavir/ombitasvir plus dasabuvir and ribavirin is well tolerated and associated with high rates of sustained virologic response in adult liver transplant recipients with recurrent HCV genotype 1 infection.

Results from the phase III ION-2 study show a 24-week regimen of sofosbuvir/ledipasvir does not produce significantly better cure rates than a 12-week regimen in treatment-experienced patients.

Results from the NEED study show combination treatment with peginterferon alpha-2a and either adefovir or entecavir does not increase HBeAg seroconversion rate compared to monotherapy alone in patients with hepatitis B.

Results from the SAPPHIRE-I trial show that Abbvie's 3D therapy produced 96% sustained viral response rates at 12 weeks in treatment-naive patient with genotype 1 hepatitis C.

Data from the PEARL-I trial of patients with hepatitis C genotype 4 show high rates of sustained virologic response at 12 weeks associated with combination treatment with ABT-450 (a protease inhibitor boosted by ritonavir) and ombitasvir.

An 8-week course of treatment with a fixed dose combination of ledipasvir plus sofosbuvir produced sustained virologic response in more than 90 percent of treatment-naïve patients with genotype 1 hepatitis C.

Results from the ELECTRON-2 study presented at EASL 2014 show treatment with fixed-dose combo of sofosbuvir and ledipasvir produced sustained virologic response in three cohorts of patients.

Study of farnesoid-x receptor agonist demonstrates protective effects on bacterial translocation from the small intestine in rat model of cholestatic liver disease.

SAPPHIRE II trial results show sustained virologic response in 96% of treatment-experienced patients with genotype 1 hepatitis C who were treated with interferon-free, triple-drug regimen.